C0007992||Pharmacological Actions
C0061355||Glucagon-Like Peptide-1
C0017132||Gastric Inhibitory Polypeptide
C0017687||Glucagon
C0017687||Glucagon family
C0597192||peptide hormones
C0030956||brain-gut peptides
C2936488||pleiotropic actions
C0008902||unique members of class B1
C0682972||G protein-coupled receptors
C0682972||G protein-coupled receptors
C0019868||homeostasis
C0085104||drug targets
C0025517||metabolic disorders
C0011860||type-2 diabetes mellitus
C0011860||type-2 diabetes mellitus
C0028754||obesity
C0027765||dysregulations of the nervous systems
C0149931||migraine
C0003469||anxiety
C0011570||depression
C0027746||neurodegeneration
C0004936||psychiatric disorders
C0007222||cardiovascular diseases
C0007992||pharmacological actions
C0087111||therapeutic advances
C0061355||glucagon-like peptide-1
C0061355||glucagon-like peptide-1
C0017132||gastric inhibitory polypeptide
C0017132||gastric inhibitory polypeptide
C0017687||glucagon